Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells 5,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 5,000 shares of the company’s stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $16.42, for a total transaction of $82,100.00. Following the transaction, the chief executive officer now directly owns 985,392 shares of the company’s stock, valued at approximately $16,180,136.64. This represents a 0.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Samuel Kintz also recently made the following trade(s):

• On Monday, March 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.83, for a total transaction of $260,375.00.

Enliven Therapeutics Trading Down 1.9 %

Shares of ELVN stock opened at $16.22 on Tuesday. The company has a market cap of $794.84 million, a PE ratio of -8.54 and a beta of 1.03. The company’s fifty day simple moving average is $19.65 and its 200-day simple moving average is $22.90. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.07. The company had revenue of $0.03 million for the quarter. Equities research analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ELVN. Invesco Ltd. boosted its position in Enliven Therapeutics by 3.5% in the 4th quarter. Invesco Ltd. now owns 15,072 shares of the company’s stock valued at $339,000 after buying an additional 508 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Enliven Therapeutics by 3.7% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company’s stock valued at $451,000 after purchasing an additional 718 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after purchasing an additional 1,114 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Enliven Therapeutics by 14.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock worth $233,000 after purchasing an additional 1,275 shares during the last quarter. Finally, MetLife Investment Management LLC increased its holdings in Enliven Therapeutics by 6.3% during the 4th quarter. MetLife Investment Management LLC now owns 21,746 shares of the company’s stock worth $489,000 after purchasing an additional 1,285 shares during the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright boosted their price objective on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, March 21st.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.